Highlights

  • Paradigm Biopharmaceuticals (ASX:PAR) has completed enrolment of 538 participants in its pivotal Phase III PARA_OA_012 trial.
  • The trial exceeded its original enrolment target of 466 participants by 15%.
  • Participants were enrolled across 65 clinical sites in Australia, the United States, Hong Kong and Moldova.
  • An independent Data Safety Monitoring Board (DSMB) interim review is expected in September 2026.
  • Full top-line Phase III efficacy results for Zilosul are targeted for the first quarter of 2027.

Paradigm Biopharmaceuticals Limited (ASX:PAR) has completed enrolment in its pivotal Phase III clinical trial evaluating Zilosul for pain associated with knee osteoarthritis, marking a key operational milestone ahead of planned interim analysis.

The PARA_OA_012 trial enrolled 538 participants across four countries, exceeding the company’s original recruitment target of 466 participants.

The completion of enrolment moves the program towards its next major milestones, including an independent Data Safety Monitoring Board (DSMB) review expected in September 2026 and full top-line results targeted for the first quarter of 2027.

Phase III Trial Completes Recruitment Ahead of Target

Paradigm confirmed that enrolment has been completed in PARA_OA_012, a Phase III trial evaluating injectable pentosan polysulfate sodium (iPPS), marketed as Zilosul, for knee osteoarthritis pain.

The trial recruited participants across 65 clinical sites located in Australia, the United States, Hong Kong and Moldova.

Participants received Zilosul at a dose of 2mg/kg administered twice weekly for six weeks. The primary endpoint measures the change from baseline in Weekly Average Daily Pain score at Day 112.

Paradigm stated that final enrolment of 538 participants exceeded the original target by approximately 15%, adding additional participants beyond the initial trial design.

Next Milestone: Independent DSMB Review

Following enrolment completion, Paradigm is preparing trial data for an interim analysis.

The company expects database lock and preparation of interim analysis data around August 2026, followed by an independent DSMB review in September 2026.

The DSMB will assess interim trial data according to pre-specified criteria. Depending on the findings, the committee may recommend continuation of the trial, identify whether early efficacy thresholds have been reached, or recommend stopping the trial for futility.

An earlier DSMB safety review, covering approximately the first 20% of treated participants, identified no material safety concerns and recommended continuation without protocol changes.

The full efficacy assessment remains dependent on completion of the trial and final analysis of the complete dataset.

Zilosul Targets Knee Osteoarthritis Pain

Zilosul is being developed as an injectable therapy for osteoarthritis and related inflammatory joint conditions.

Paradigm’s Phase III program is focused on assessing whether Zilosul can reduce pain associated with knee osteoarthritis.

Osteoarthritis remains a major area of unmet need, with current treatment Options primarily focused on symptom management, including pain relief, corticosteroid injections and eventual joint replacement procedures.

A successful Phase III outcome would provide clinical evidence supporting the potential use of Zilosul in this treatment area. However, enrolment completion confirms trial execution and recruitment progress rather than clinical efficacy.

Clinical Program Supported by Multi-Country Trial Design

Paradigm is a clinical-stage biopharmaceutical company focused on repurposing pentosan polysulfate sodium (PPS) as an injectable treatment for osteoarthritis and inflammatory joint conditions.

The company’s lead program, Zilosul, is being evaluated through its Phase III knee osteoarthritis trial, which is designed to support potential future regulatory pathways in Australia and the United States if results are positive.

Paradigm has previously received U.S. Food and Drug Administration (FDA) Fast Track Designation for its Phase III osteoarthritis program.

The company’s development strategy remains centred on generating clinical data from the PARA_OA_012 trial.

Funding Position Remains a Key Consideration

Paradigm reported cash on hand of approximately A$15.37 million as at the June 2026 quarter.

Following the quarter, the company received a further A$5.69 million in tax refunds and drew down A$4.6 million under a convertible note facility, with approximately A$10.7 million remaining available under that facility.

Quarterly operating cash outflow was approximately A$13.54 million, including around A$13.3 million in Research and Development expenditure associated with the Phase III trial.

Paradigm also raised A$21.38 million through an institutional Placement and Share Purchase Plan.

The company has approximately 117 million attaching options on issue, which could generate additional proceeds if exercised, subject to option holder decisions and market conditions.

What Investors Are Watching Next

The next major milestones for Paradigm are expected to occur in sequence, beginning with database lock and interim data preparation around August 2026.

The September 2026 DSMB review will provide the next formal assessment point before the company progresses towards full top-line Phase III results expected in the first quarter of 2027.

Investors may also continue monitoring the company’s funding position, given ongoing research and development expenditure associated with the large multi-country clinical program.

Investor Takeaway

Paradigm Biopharmaceuticals has completed recruitment for its Phase III Zilosul osteoarthritis trial ahead of its original target, moving the program closer to key clinical data milestones.

The September DSMB review and first-quarter-2027 topline results remain the central upcoming events for the program. While enrolment completion demonstrates trial execution progress, the clinical efficacy outcome will depend on the final trial data.

Funding requirements, trial progression and regulatory developments will remain important factors as Paradigm advances towards completion of the Phase III program.